These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29533117)

  • 1. Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors.
    Dashti-Khavidaki S; Khalili H; Nasiri-Toosi M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):525-529. PubMed ID: 29533117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
    Michal JL; Rab S; Patel M; Kyle AW; Miller LS; Easley KA; Kalapila AG
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):690-698. PubMed ID: 29766745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
    Bunnell KL; Vibhakar S; Glowacki RC; Gallagher MA; Osei AM; Huhn G
    Pharmacotherapy; 2016 Sep; 36(9):e148-53. PubMed ID: 27459733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
    Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
    Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.
    Maan R; Al Marzooqi SH; Klair JS; Karkada J; Cerocchi O; Kowgier M; Harrell SM; Rhodes KD; Janssen HLA; Feld JJ; Duarte-Rojo A
    Aliment Pharmacol Ther; 2017 Jul; 46(1):46-55. PubMed ID: 28470850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration.
    Lee EJ; Jang HN; Cho HS; Bae E; Lee TW; Chang SH; Park DJ
    Ren Fail; 2018 Nov; 40(1):687-692. PubMed ID: 30741619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Sofosbuvir and Ribavirin for Eradicating Hepatitis C Virus in Renal Transplant Recipients in Pakistan: Where Resources Are Scarce.
    Hanif FM; Laeeq SM; Mandhwani RK; Luck NH; Aziz T; Mehdi SH
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):63-67. PubMed ID: 28260436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
    Singh T; Guirguis J; Anthony S; Rivas J; Hanouneh IA; Alkhouri N
    Liver Int; 2016 Jun; 36(6):802-6. PubMed ID: 26824848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity as a cause of acute kidney injury in children.
    Patzer L
    Pediatr Nephrol; 2008 Dec; 23(12):2159-73. PubMed ID: 18228043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
    Patel N; Bichoupan K; Ku L; Yalamanchili R; Harty A; Gardenier D; Ng M; Motamed D; Khaitova V; Bach N; Chang C; Grewal P; Bansal M; Agarwal R; Liu L; Im G; Leong J; Kim-Schluger L; Odin J; Ahmad J; Friedman S; Dieterich D; Schiano T; Perumalswami P; Branch A
    World J Gastroenterol; 2016 Mar; 22(9):2844-54. PubMed ID: 26973423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment.
    Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C
    J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.
    Qu Y; Guo Y; Li T; Ye Q; Sun C; Wang L; Yang B
    J Gastroenterol Hepatol; 2017 Apr; 32(4):740-748. PubMed ID: 27749979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT
    J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir and velpatasvir for the treatment of hepatitis C.
    Jackson WE; Everson GT
    Expert Rev Gastroenterol Hepatol; 2017 Jun; 11(6):501-505. PubMed ID: 28468532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Naggie S; Marks KM; Hughes M; Fierer DS; Macbrayne C; Kim A; Hollabaugh K; Roa J; Symonds B; Brainard DM; McHutchison JG; Peters MG; Kiser JJ; Chung R;
    Clin Infect Dis; 2017 Apr; 64(8):1035-1042. PubMed ID: 28329053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
    Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
    Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.